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ARTICLE
MRE11 and EXO1 nucleases degrade reversed forks
and elicit MUS81-dependent fork rescue in BRCA2-
deﬁcient cells
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The breast cancer susceptibility proteins BRCA1 and BRCA2 have emerged as key stabilizing
factors for the maintenance of replication fork integrity following replication stress. In their
absence, stalled replication forks are extensively degraded by the MRE11 nuclease, leading to
chemotherapeutic sensitivity. Here we report that BRCA proteins prevent nucleolytic
degradation by protecting replication forks that have undergone fork reversal upon drug
treatment. The unprotected regressed arms of reversed forks are the entry point for MRE11 in
BRCA-deﬁcient cells. The CtIP protein initiates MRE11-dependent degradation, which is
extended by the EXO1 nuclease. Next, we show that the initial limited resection of the
regressed arms establishes the substrate for MUS81 in BRCA2-deﬁcient cells. In turn, MUS81
cleavage of regressed forks with a ssDNA tail promotes POLD3-dependent fork rescue. We
propose that targeting this pathway may represent a new strategy to modulate BRCA2-
deﬁcient cancer cell response to chemotherapeutics that cause fork degradation.
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Germline mutations in the Breast Cancer Susceptibilitygenes BRCA1/BRCA2 account for the vast majority offamilial breast cancer cases1–4. Aside from their well-
established roles in homologous recombination (HR), BRCA
proteins are emerging as key factors required for the maintenance
of replication fork stability following replication stress
induction5–8. In their absence, replication forks are extensively
degraded by the MRE11 nuclease. MRE11-dependent degradation
of replication forks observed in the absence of BRCA proteins
leads to long stretches of ssDNA (>4–5 kb) and is emerging as
one of the leading causes of the sensitivity to therapies that target
DNA or that inhibit speciﬁc repair pathways such as PARP
inhibitors5. The mechanism leading to this extensive fork
degradation phenotype in the absence of BRCA1 or BRCA2
remains unclear. For example, the exact structure(s) of the
replication intermediates targeted by nucleases in BRCA-deﬁcient
cells is unknown. Moreover, MRE11 has limited nucleolytic
activity9 and is unlikely to be the only nuclease responsible for
degrading several kb of DNA in BRCA-deﬁcient cells. Finally, the
fate of the extensively resected forks upon drug removal has never
been investigated in detail, even though it is tightly linked to the
increased chromosomal aberrations and DNA damage sensitivity
of BRCA-deﬁcient cells.
Replication fork reversal is a key protective mechanism that
allows replication forks to reverse their course when they
encounter DNA lesions10–14. Interestingly, the same HR factors
controlling MRE11 nuclease activity and ssDNA accumulation
are also emerging as crucial players involved in fork
remodeling14–16. In particular, the central recombinase RAD51 is
essential for fork reversal upon chemotherapeutic treatment14. By
analogy with its bacterial homologue RecA, RAD51 may be
recruited to ssDNA stretches formed at replication fork junctions
and promote the initial step of fork reversal by invading the
complementary strand. In this context, HR proteins may also be
required to stabilize forks in their reversed state by protecting the
double-stranded end of the regressed arm from nucleolytic
degradation.
In this study, we combine electron microscopy (EM) with
genome-wide single-molecule DNA ﬁber approaches to deﬁne the
mechanism by which the BRCA proteins protect replication forks
from nucleolytic degradation following replication stress induc-
tion. We show that the main function of BRCA proteins in this
context is to protect the regressed arms of replication forks that
have reversed upon drug treatment from nucleolytic degradation.
In their absence, CtIP initiates the MRE11-dependent degrada-
tion of the unprotected regressed arms and EXO1 contributes to
extend fork degradation. Next, we investigate how cells cope with
these extensively resected forks upon drug removal. In particular,
we ﬁnd that MUS81 cleavage rescues the resected forks in
BRCA2-, but not BRCA1-deﬁcient cells through a break-induced
replication (BIR)-like mechanism mediated by POLD3-
dependent DNA synthesis. Our ﬁndings revisit the functions of
central HR factors in DNA replication and are crucial to
understanding how targeting BIR-dependent pathways can
modulate current chemotherapeutic modalities.
EXO1 contributes to fork resection in BRCA-deﬁcient cells.
Two distinct pathways act redundantly to mediate processive
double-strand break (DSB) resection downstream from the
MRE11-RAD50-NBS1 (MRN) and CtIP factors in eukaryotic
cells: one requires DNA2 and the other EXO117–21. We sought to
investigate whether DNA2 and EXO1 also contribute to the
extended fork degradation phenotype of BRCA1- or BRCA2-
deﬁcient cells following genotoxic stress induction. We knocked
down EXO1 or DNA2 in different cell lines, including the
BRCA2-mutant ovarian cancer cells PEO1 (and the isogenic
PEO4 cells, which contain a second point mutation restoring
BRCA2 function), the Fanconi anemia BRCA2-mutant line
EUFA423 (and its derivative expressing wild-type BRCA2), the
BRCA1 mutant ovarian cancer cell line UWB1.289 (and its
complemented derivative expressing wild-type BRCA1), plus the
human osteoscarcoma U2OS cells, which were siRNA-depleted
for BRCA1 or BRCA2. Nucleolytic resection following replication
fork stalling was monitored by pulse-labeling cells with the ﬁrst
thymidine analog IdU (red label) followed by treatment with
hydroxyurea (HU) and concomitant labeling with the second
thymidine analog, CldU (green label) (Fig. 1a). Shortening of the
ﬁrst tract was measured as a readout of degradation only on forks
characterized by contiguous IdU-CldU signals (and not on forks
that have only the IdU label) to ensure that the shortening phe-
notype is indeed due to nucleolytic resection of stalled replication
forks and not to premature termination events22. Upon HU
treatment, BRCA1- and BRCA2-deﬁcient cells showed a marked
reduction (30–50% corresponding to> 5 kb of DNA) in the IdU
tract length (Fig. 1b, c and Supplementary Fig. 1a). Moreover,
MRE11 inhibition or knockdown partially rescued fork degra-
dation consistent with the previous data5–7 (Fig. 1b, c and Sup-
plementary Fig. 1). Analogous results were obtained using an
alternative labeling scheme, where HU was added after thymidine
labeling, suggesting that the results were not affected by the
particular labeling scheme used in our work (Supplementary
Fig. 1b). EXO1 knockdown by two different siRNAs yielded the
same fork protection phenotype observed with MRE11 inhibition,
indicating that EXO1 also contributes to fork degradation in
BRCA1- and BRCA2-deﬁcient cells upon HU treatment (Fig. 1
and Supplementary Figs. 1a–e and 2a, b). Interestingly, combined
ablation of MRE11 and EXO1 activities further rescued the fork
degradation phenotype of BRCA-deﬁcient cells, suggesting that
the two nucleases may be able to act independently on the stalled
replication intermediates. The same results were obtained by
treating BRCA2-deﬁcient cells with DNA damaging agents such
as cisplatin or UV-C, supporting the notion that different geno-
toxic agents trigger a similar fork resection mechanism whereby
MRE11 and EXO1 extensively degrade replication forks in the
absence of key HR factors (Supplementary Fig. 3a, b). Conversely,
DNA2 knockdown did not restore fork protection (Supplemen-
tary Fig. 2c–g), in agreement with previous ﬁndings23. The same
results were recapitulated by treating BRCA2-deﬁcient cells with
the NSC-105808 DNA2 inhibitor24 (Supplementary Fig. 2e).
Taken together, these results suggest that human EXO1, but not
DNA2, contributes to replication fork degradation in BRCA1-
and BRCA2-deﬁcient cells.
MRE11 and EXO1 target reversed forks in BRCA-deﬁcient
cells. Next, we sought to investigate the actual structure(s) of the
replication intermediates targeted by MRE11 and EXO1 in
BRCA1- or BRCA2-deﬁcient cells. We visualized the ﬁne archi-
tecture of the replication intermediates using a combination of
in vivo psoralen cross-linking and EM25 (Fig. 2a). Our analysis
showed a substantial fraction of reversed replication forks (~25%
of molecules analyzed) in control U2OS cells treated with 4 mM
HU, consistent with previous data14, 26 (Fig. 2b). BRCA1- or
BRCA2-knockdown resulted in a signiﬁcantly lower frequency of
fork reversal events (~10 and 11%, respectively) compared to
HU-treated control cells, suggesting that BRCA proteins are
required either to promote fork reversal or to prevent nucleolytic
processing of forks that have already reversed following HU
treatment. To distinguish between these two possibilities, we
repeated the EM analysis while inhibiting MRE11 activity or
knocking down EXO1 in BRCA-deﬁcient cells. We found that
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ablation of either nuclease rescues the frequency of reversed forks
to levels observed in control cells, suggesting that BRCA proteins
protect forks that have already undergone fork reversal from
nucleolytic degradation. Similar results were obtained by inhi-
biting MRE11 in BRCA2-mutant PEO1 cells (Fig. 2c). Time-
course experiments performed by treating BRCA2-deﬁcient
U2OS cells with HU for 0, 30, or 120 min indicated that fork
reversal precedes fork degradation, as predicted by our model
(Fig. 2d–f). Collectively, these results suggest that BRCA proteins
protect reversed forks from nucleolytic degradation and that the
unprotected reversed forks are the entry point for MRE11 and
EXO1 in BRCA1- and BRCA2-deﬁcient cells.
CtIP initiates MRE11-dependent resection of reversed forks.
The regressed arm of a reversed replication fork resembles by all
means a one-ended DSB. Previous biochemical studies showed
that the 5′–3′ endonuclease activity of MRE11 initiates the
resection process and that CtIP is required to promote MRE11
endonuclease activity at the 5′ strand27. Resection is then con-
tinued by the 5′–3′ exonuclease activity of EXO119, 28, 29. As an
alternative approach to conﬁrm that MRE11-dependent resection
starts from the regressed arm of reversed replication forks, we
repeated the DNA ﬁber experiments with CtIP knockdown cells
and found that CtIP loss prevents fork degradation in BRCA2-
deﬁcient cells (Supplementary Fig. 3c, d). These data suggest that
the same pathway that initiates DSB resection in the context of
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Fig. 1 MRE11 and EXO1 mediate extended nascent strand degradation in HU-treated BRCA1- and BRCA2-deﬁcient cancer cells. a Schematic of the single-
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indicated. Out of 3 repeats; n≥ 250 tracts scored for each data set. Bars represent the median. Statistics: Mann–Whitney; ****P< 0.0001. c Size
distribution of IdU tract length in BRCA1-deﬁcient U2OS (left) and UWB1 (right) cells in the presence and absence of HU. Cells were transfected with
control siRNA or EXO1 siRNA before IdU and CldU labeling. Mirin (50 μM) was added concomitantly with HU treatment, as indicated. Out of 2 repeats; n≥
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HR is required to process the open dsDNA end of the regressed
arm. To further validate this conclusion, we reasoned that
degradation should not take place in a genetic background that
prevents reversed fork formation—i.e., RAD51 knockdown14.
Indeed, loss of RAD51 suppressed fork degradation in BRCA2-
depleted U2OS cells, conﬁrming that RAD51 acts upstream of
BRCA2 to promote reversed fork formation (Fig. 3a, b). In
addition, RAD51 depletion severely compromised fork restart,
suggesting that fork remodeling is an essential requirement for
efﬁcient resumption of DNA synthesis upon HU removal
(Figs. 3c, d).
Resection does not affect fork restart upon BRCA2 loss. The
extended nucleolytic degradation of stalled replication
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intermediates in BRCA1- and BRCA2-deﬁcient cells leads to
increased chromosomal aberrations and genome instability5, 6.
However, the molecular mechanism linking fork degradation
with chromosomal instability remains elusive. Thereby, we set out
to investigate how cells cope with these extensively degraded forks
focusing on BRCA2-deﬁcient cells. Fork degradation associated
with BRCA2 loss did not signiﬁcantly affect fork restart (Fig. 3e),
in agreement with previous ﬁndings5, 6. However, by increasing
the timing of CldU labeling from 15 to 90 min, we found that
thymidine incorporation after HU removal was reduced in
BRCA2-deﬁcient compared to BRCA2-proﬁcient cells (Fig. 3f).
This reduction in the CldU tract length suggests that BRCA2 loss,
though not affecting the number of restarting forks, either
impairs fork progression after restart or causes a delayed restart of
the resected forks. Ablation of MRE11 and/or EXO1 activity
rescued CldU tract length, suggesting that the extended nascent
strand degradation associated with BRCA2 loss is the leading
cause of the observed defect in fork progression or timing of
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restart (Fig. 3f). Moreover, BRCA2 loss led to increased chro-
mosomal aberrations when cells were challenged with HU, and
this effect was again partially rescued by ablation of MRE11 and/
or EXO1 activity, supporting a link between fork degradation,
defects in fork progression or restart upon drug removal and
increased chromosomal aberrations (Fig. 3g).
MUS81 cleaves partially resected reversed forks. We next
examined the mechanism that rescues resected forks upon drug
removal. Using neutral comet assays we found that BRCA2 loss
leads to DSB accumulation upon HU treatment (Figs. 4a, b).
However, the frequency of DSBs decreased to control levels
15 min after HU removal, suggesting that these DSBs are quickly
repaired after fork restart. Interestingly, MUS81 depletion pre-
vented DSB accumulation in BRCA2-deﬁcient cells (Fig. 4c). A
short-interfering RNA (siRNA)-resistant MUS81 cDNA, but not
a catalytically inactive version (MUS81(D338A/D339A)), restored
DSB accumulation in MUS81 siRNA-depleted cells (Fig. 4c and
Supplementary Fig. 3f). Therefore, we propose that MUS81
endonuclease activity is required to cleave partially resected forks,
leading to transient DSB accumulation in the absence of BRCA2.
Our observation that MUS81 loss did not signiﬁcantly affect fork
resection supports the idea that the extended fork degradation
phenotype was not due to the resection of the DSBs created by
MUS81 cleavage (Supplementary Fig. 3g). Moreover, the notion
that MUS81 acts downstream of MRE11 and EXO1 was sup-
ported by the observation that the DSB accumulation of BRCA2-
deﬁcent cells was signiﬁcantly reduced in a genetic background
that prevents fork resection—i.e., loss of MRE11, EXO1, or CtIP
activity (Fig. 4c and Supplementary Fig. 3e).
To deﬁne the exact substrate cleaved by MUS81 in BRCA2-
deﬁcient cells, we inspected the structure of the replication
intermediates that accumulate in BRCA2-deﬁcient cells upon
MUS81 depletion. Our EM analysis revealed that MUS81 loss
causes a dramatic increase in reversed fork frequency in BRCA2-
deﬁcient cells (Fig. 5a, b). Next, we evaluated the ssDNA
composition of the regressed arms by detecting local differences
in ﬁlament thickness. MUS81 depletion led to a signiﬁcant
increase in the percentage of regressed forks that are partially or
entirely single-stranded, strongly suggesting that MUS81 cleaves
partially resected regressed forks with a ssDNA tail (Fig. 5b).
Interestingly, MUS81 depletion also led to a signiﬁcant increase in
the percentage of daughter strands with ssDNA at the fork
junction, suggesting that in the absence of MUS81 cleavage
asymmetric fork resection continues beyond the length of the
regressed arm, leading to partially resected 3-way junction
structures (Fig. 5c). Of note, the small fraction of HU-induced
DSBs of BRCA2-proﬁcient cells is also rescued by the loss of
MUS81, but not of MRE11 or EXO1 (Supplementary Fig. 3h).
This observation is consistent with the previous biochemical data
showing that MUS81 can also cleave intact forks, although with
much lower efﬁciency compared to ﬂap-fork substrates30. Taken
together, these results suggest that the initial resection of the
regressed arms leads to the formation of reversed forks with a
ssDNA ﬂap, which are cleaved by MUS81.
MUS81 cleavage promotes POLD3-dependent DNA synthesis.
To test whether MUS81-dependent cleavage of resected regressed
forks is required for fork restart, we quantiﬁed the percentage of
stalled forks in MUS81 and BRCA2 co-depleted cells (Fig. 5d).
MUS81 loss slightly increased fork stalling in BRCA2-proﬁcient
cells, in agreement with previous ﬁndings31, 32. This effect was
signiﬁcantly more dramatic in the absence of BRCA2 and was
conﬁrmed using two different MUS81 siRNAs (Fig. 5d and
Supplementary Fig. 4a, b). Genetic knockdown–rescue experi-
ments conﬁrmed that complementation in MUS81-depleted
U2OS cells with siRNA-resistant wild-type MUS81, but not
with the catalytically inactive mutant, abrogated the effect of
MUS81 depletion on replication fork stalling upon HU treatment
(Fig. 5d).
MUS81 has two partners in human cells, EME1 and EME2,
and the two proteins are thought to interact with MUS81 at
different stages of the cell cycle. Genetic knockdown experiments
showed that EME2, but not EME1, is involved in the same fork
restart pathway, suggesting that the function of the MUS81-
EME2 complex is restricted to the S-phase (Supplementary
Fig. 4c, d), in agreement with previous ﬁndings32. MUS81
cleavage was previously shown to promote POLD3-dependent
DNA synthesis at common fragile sites33 and telomeric34 loci in
human cells. POLD3 is one of the accessory subunits of the
replicative polymerase POL δ and was recently shown to be
required for BIR, a specialized HR pathway to repair DSBs at
stalled forks35, 36. Similar to MUS81 depletion, POLD3 loss
increased fork stalling in BRCA2-deﬁcient cells (Fig. 6a and
Supplementary Fig. 4e). Moreover, it led to a severe defect in fork
progression, suggesting that POLD3-dependent DNA synthesis is
required to restart the MUS81-cleaved resected forks (Fig. 6b).
Interestingly, POLD3/BRCA2 double depletion caused a further
increase in DSB accumulation compared to depletion of BRCA2
alone and these DSBs were again rescued by MUS81 depletion
conﬁrming that POLD3 acts downstream of MUS81 in the
pathway (Fig. 6c). The notion that BRCA2-deﬁcient cells rely on
the MUS81-dependent pathway to resume DNA synthesis is
supported by our observation that cell viability is reduced in
MUS81/BRCA2 co-depleted cells relative to BRCA2-depleted
cells following HU treatment (Fig. 5e). Conversely, PARP
Fig. 3 Resected forks are able to restart in BRCA2-deﬁcient cells and lead to increased chromosomal aberrations. a Expression of RAD51 after siRNA
knockdown in U2OS cells. b Size distribution of IdU tract length in BRCA2-deﬁcient and -proﬁcient U2OS cells in the presence and absence of HU. Cells
were transfected with control siRNA (siNEG), RAD51 siRNA, or BRCA2 siRNA before IdU and CldU labeling. Out of 2 repeats; n≥ 250 tracts scored for each
data set. Bars represent the median. Statistics: Mann–Whitney; ****P< 0.0001. c Schematic of the single-molecule DNA ﬁber tract analysis for the fork
restart experiments. Red-green contiguous tracts (restarting forks). Red only tracts (stalled/terminated forks). d Quantiﬁcation of restarting forks in
BRCA2-deﬁcient and -proﬁcient U2OS cells with or without RAD51 siRNA knockdown. Out of 2 repeats, the percentage is established on at least 250 tracts
scored for each data set. Mean shown. Errors, S.E.M. Statistics: unpaired t test; **P< 0.01. e Quantiﬁcation of restarting forks in BRCA2-deﬁcient and
-proﬁcient U2OS cells with or without EXO1 siRNA knockdown. Mirin (50 μM) was added concomitantly with HU treatment, as indicated. Out of 2 repeats,
the percentage is established on at least 250 tracts scored for each data set. Mean shown. Errors, S.E.M. f Size distribution of CldU tract length in BRCA2-
deﬁcient and -proﬁcient U2OS cells in the presence of HU. Cells were transfected with control siRNA (siNEG), EXO1 siRNA, or BRCA2 siRNA before IdU
and CldU labeling. Mirin (50 μM) was added concomitantly with HU treatment, as indicated. Out of 2 repeats; n≥ 250 tracts scored for each data set. Bars
represent the median. Statistics: Mann–Whitney; ****P< 0.0001. g Chromosomal aberrations in BRCA2-deﬁcient and -proﬁcient U2OS cells in the
presence of HU. Left, representative images of metaphase spreads in the presence of HU. Scale bar, 25 μm. Sketch above the images delineates
experimental design. Right, numbers of chromosomal aberrations per metaphase are plotted. At least 50 metaphases counted in each experiments. Mean
shown, n= 3.. Errors, S.E.M. Statistics: unpaired t test: ****P< 0.0001
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inhibitor sensitivity was not signiﬁcantly affected by MUS81
depletion consistent with the notion that PARP inhibitors,
differently from HU, prevent reversed fork accumulation10, 13
and thereby do not require a MUS81-dependent pathway of fork
rescue (Supplementary Fig. 4f). Collectively, these results suggest
that BRCA2-deﬁcent cells rely on a MUS81/POLD3-dependent
mechanism to rescue resected replication forks following
treatment with genotoxic agents that induce replication fork
reversal and degradation in a BRCA2-deﬁcient background.
MUS81 does not rescue forks in BRCA1-deﬁcient cells. Our
data suggest that BRCA1 shares a function similar to BRCA2 in
reversed fork protection (Fig. 1). However, the MUS81 pathway is
not required to rescue forks in BRCA1-deﬁcient cells (Supple-
mentary Fig. 4g, h), suggesting that different pathways mediate
the restart of the resected forks depending on the particular
genetic background. These ﬁndings are in agreement with recent
studies, suggesting that MUS81 depletion differentially affects
chemotherapeutic sensitivity in BRCA2- versus BRCA1-deﬁcient
cells (Alan D’Andrea personal communication) and with our
immunoﬂuorescence experiments showing that MUS81 and
POLD3 foci accumulate speciﬁcally in BRCA2-, but not in
BRCA1-deﬁcient cells (Fig. 6d).
Discussion
This work deﬁnes the mechanism that leads to the extensive fork
degradation phenotype observed in BRCA2-deﬁcient cells and
provides novel insights into the molecular steps that rescue the
resected forks upon drug removal. We propose a model whereby
BRCA2 protects the regressed arms of replication forks that have
reversed upon drug treatment from nucleolytic degradation. In its
absence, the double-stranded ends formed by fork reversal are
targeted by the CtIP, MRE11, and EXO1 nucleases to initiate the
degradation of the stalled replication intermediates (Fig. 6e).
Recent data suggest that RAD51 promotes reversed fork forma-
tion14 and is enriched on nascent DNA independently of
BRCA25. We propose that RAD51 has two distinct functions
during replication stress: a BRCA2-independent function in
promoting the initial step of reversed fork formation and a
BRCA2-dependent function, whereby BRCA proteins protect the
already formed reversed forks from nucleolytic degradation by
stabilizing the RAD51 ﬁlament on the regressed arm. In BRCA2-
deﬁcient cells, this second function is lost, leading to the nascent
strand degradation phenotype observed with BRCA2 mutants
unable to stabilize RAD51 on ssDNA6 or with RAD51 mutants
that destabilize the RAD51 nucleoﬁlament37, 38. Because of the
severe defect in fork restart associated with RAD51 depletion are
reported here, we also suggest that fork remodeling is a central
mechanism of replication stress response following prolonged
drug treatment. Collectively, these ﬁndings shed light on the long-
debated function of central HR factors in fork remodeling and go
beyond the oversimpliﬁed concept that HR factors are simply
required for DSB repair during replication stress. Our ﬁndings
also reveal that MUS81-dependent cleavage of the resected forks
is required for fork restart in BRCA2-deﬁcient cells. The dis-
covery that replication stalling induces RAD51 foci formation in a
MUS81-independent manner is consistent with the idea that
MUS81 is required to cleave forks that have already undergone
RAD51-dependent fork remodeling31. We propose that MUS81
acts downstream of MRE11- and EXO1-mediated degradation.
On the basis of our ﬁndings that CtIP is required to promote fork
resection and MRE11 endonuclease activity at the 5′ strand, we
also propose that the initial degradation of the regressed arms
generates a reversed fork with a 3′-ssDNA tail that is then cleaved
by MUS81 to mediate fork restart. This notion is consistent with
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the in vitro data showing that MUS81 efﬁciently cleaves 3′ ﬂaps,
Y-shaped structures and nicked Holliday junctions (HJ), but has
negligible activity toward intact HJs (resembling an intact
reversed fork substrate)30, 39, 40. In the absence of MUS81 clea-
vage, the nucleolytic degradation might quickly proceed to
degrade nascent strands behind the junction ﬁnally leading to the
extensively resected forks observed by DNA ﬁber (Supplementary
Fig. 4i). Recent studies suggest that completion of DNA replica-
tion at common fragile sites33 and telomeric34 loci occurs via a
specialized form of DNA repair originally characterized in yeast
and termed BIR, whereby MUS81 cleavage of stalled replication
forks produces a migrating bubble that drives POLD3-dependent
DNA synthesis41, 42, 43. We propose that a similar mechanism is
responsible to rescue partially resected regressed forks in BRCA2-
deﬁcient cells. We speculate that the MUS81/POLD3-dependent
pathway used to rescue resected forks in BRCA2-deﬁcient cells
might represent a novel anticancer drug target speciﬁc for
BRCA2-defective tumors to be used in combination with che-
motherapeutics that cause replication fork reversal and
degradation.
Methods
Cell lines and culture conditions. Cell lines: the human osteosarcoma U2OS cells
(American Type Culture Collection), BRCA2-mutant ovarian cancer cells PEO1
(and the isogenic PEO4 cells, which contain a second point mutation restoring
BRCA2 function) (provided by Dr. Lee Zou, Harvard Medical School)44, Fanconi
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anemia BRCA2-mutant line EUFA423 (and its derivative expressing wild-type
BRCA2) (provided by Dr. Douglas Bishop, University of Chicago)45, BRCA1
mutant ovarian cancer cell line UWB1.289 (and its complemented derivative
expressing wild-type BRCA1) (provided by Dr. Lee Zou, Harvard Medical School)46.
U2OS and EUFA 423 F/HAB245 cells were grown in DMEM media supplemented
with 10% fetal bovine serum (FBS), 100 Uml−1 penicillin and 100 μg ml−1 strep-
tomycin at 37 °C in 5% CO2. Ovarian cancer PEO4/PEO144 were cultivated
in RPMI media supplemented with 10% fetal bovine serum (FBS), 100 Uml−1
penicillin and 100 μg ml−1 streptomycin and UWB1/UWB1 + BRCA146 cells
were grown in 50% RPMI media, 50% MEGM bullet kit (Lonza CC-3150) com-
pleted with 3% FBS, 100 Uml−1 penicillin and 100 μg ml−1 streptomycin at 37 °C in
5% CO2.
Drug and reagents. The MRE11 inhibitor Mirin was from Sigma-Aldrich. The
NSC-105808 DNA2 inhibitor was a gift from Gregorz Ira24. The DNA2 inhibitor
was used at a concentration of 0.3 μM for 24 h. Hydroxyurea (Sigma-Aldrich) was
dissolved in double-distilled H2O to obtain a 100 mM (7.6 mgml−1) solution.
Cisplatin (Sigma-Aldrich) was dissolved in PBS 10× to obtain a 5 mM stock. UV-C
was used at 40 mJ cm−2 as described in the labeling scheme. The MUS81 vectors
used for the genetic complementation experiments was a gift from by Ian Hick-
son33. All vectors were ampliﬁed in DH5α Escherichia coli and extracted with
GeneJET Plasmid Midiprep Kit (ThermoFisher Scientiﬁc).
RNA interference. All transient gene depletions were carried out using the
Lipofectamine RNAiMax transfection reagent (Life Technologies), except for EXO1
gene silencing that was performed using TransIT-siQuest (Mirus). SMARTpool
siRNA from Dharmacon were employed to deplete the following genes: BRCA2 (L-
003462-00, 10 nM, 24 or 48 h) as described47, BRCA1 (L-003461-00, 50 nM, 48 h)
as described48, MRE11A (L-009271-00, 40 nM, 48 h) as described49, MUS81
(siRNA2: L-016143-01, 20 nM, 48 h) as described50, POLD3 (L-026692-01, 50 nM,
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48 h), as described33. The following genes were depleted with siRNA purchased
from Ambion: DNA2 (4390827, 10 nM, 48 h), EXO1 (#1: 4392420 and #2: S17502,
40 nM, 48 h), RAD51 (4390827, 50 nM, 48 h) and MUS81 in rescue experiments
(AM16708, 25 nM, 48 h). The EME2 siRNA was purchased from Qiagen (Gene-
Solution 146956, 80 nM, 48 h). The EME2 and CtIP siRNAs were custom made:
EME2 (5′-GCGAGCCAGUGGCAAGAGA-3′, 40 nM, 48 h) as described32 and
CtIP (5′-GCUAAAACAGGAACGAAUC-3′, 50 nM, 48 h) as described20. Silencer
select negative control siRNA (4390843, Ambion) was used for the control
experiments.
RT-qPCR and western blot analysis. The levels of siRNA-mediated knockdowns
were determined by RT-qPCR or western blot. mRNAs was extracted with the
PureLink RNA mini kit (Invitrogen) and cDNA was synthesized using the M-MLV
reverse Transcriptase (Life Technologies) according to the manufacturer’s indica-
tions. RT-qPCR experiments were performed using the following primers: BRCA1
(5′- AGAAACCACCAAGGTCCAAAG-3′ and 5′-GGGCCCATAGCAACA-
GATTT-3′), BRCA2 (5′- AGGACTTGCCCCTTTCGTCTA-3′ and 5′-TGCAG-
CAATTAACATATGAGG-3′), CtIP (5′-AAGAGGAGGAATTGTCTACTGC-3′
and 5′-AGAATCTTGTCCCCTGTGGTGGA-3′), DNA2 (5′- ATTAG-
CATTTGGCGTGTGGC-3′ and 5′-CTTTCTGTGTTACCCCCGGT-3′), EME1
(5′-CTCATCCCTGAGGGCTAGAA-3′ and 5′-AGTTGAAAGAGTGGCGGGA-
3′), EME2 (5′-AGGTGGAAGAGGCCCTGGTA-3′ and 5′-CCCTGCTGTGCA-
GAAGGAGA-3′), EXO1 (5′- CCTCGTGGCTCCCTATGAAG-3′ and 5′-AGGA-
GATCCGAGTCCTCTGTAA-3′), GAPDH (5′- GAGCCACATCGCTCAGAC-3′
and 5′-GACCAGGCGCCCAATAC-3′), MRE11 (5′- CCAGA-
GAAGCCTCTTGTACG-3′ and 5′-TTCCACCTCTTCGACCTCTTC-3′), MUS81
(5′- CTAACGAGAGGAGAGCCTGC-3′ and 5′-GAGTGGAGCCAAGG-
GAAAAGA-3′), and POLD3 (5′- GAGTTCGTCACGGACCAAAAC-3′ and 5′-
GCCAGACACCAAGTAGGTAAC-3′). Reactions were realized using the iQTM
SYBR® Green supermix (Bio-Rad) following to the manufacturer’s instructions.
For each sample, normalization was performed using GAPDH. Results were
expressed relative to indicated controls.
For western blot analysis, cells were lysed in a buffer containing 100 mM Tris-
HCl, 4% SDS, 20% glycerol, β-mercaptoethanol (100 μl ml−1). 20 μg of protein
extracts were loaded onto a NuPAGE™ Novex™ 3-8% Tris-Acetate Protein Gels,
1.0 mm, 15-well (ThermoFisher Scientiﬁc). Proteins were transferred onto a
nitrocellulose membrane (GE HealthCare) for 1 h at 15 V using the dry transfer
machine Pierce G2 (ThermoFisher Scientiﬁc) following the manufacturer’s
instruction. Membranes were blocked for 1 h in TBS containing 0.1% Tween 20.
Next, membranes were probed with the anti-RAD51 rabbit polyclonal (1:1000; 05-
530-I Sigma-Aldrich), anti-EXO1 rabbit polyclonal (1:1000; provided by Dr.
Zhongsheng You), anti-BRCA1 mouse monoclonal (1:1000; ab16781 Abcam), anti-
BRCA2 mouse monoclonal (1:1000; OP95 EMD-Millipore), anti-β-actin HRP
(1:5000; A3854 Sigma-Aldrich) or anti-β tubulin rabbit polyclonal (1:5000; sc-9104,
Santa Cruz Biotechnology, Inc.) antibodies. Proteins were visualized using ECL
(Pierce) according to the manufacturer’s instructions.
DNA ﬁber assay. Brieﬂy, asynchronously growing cells were labeled with two
thymidine analogs: 20 μM 5-iodo-2′-deoxyuridine (IdU; Sigma-Aldrich) followed
by 200 μM 5-chloro-2′-deoxyuridine (CldU; Sigma-Aldrich) for the indicated
times13, 51. Cells were washed twice with PBS after the ﬁrst pulse and treated with
the indicated doses of the genotoxic agents. After the indicated times, cells were
collected and resuspended in PBS at 100,000 cells per ml. A total of 2 μl of this cell
solution was mixed with 8 μl of lysis buffer (200 mM Tris.HCl pH 7.5; 50 mM
EDTA; 0.5 % SDS) on a glass slide. After 6 min, the slides were tilted at a 20–45°
angle, and the resulting DNA spreads were air dried, ﬁxed in 3:1 methanol/acetic
acid and stored at 4 °C. The DNA ﬁbers were denatured with 2.5 M HCl for 1 h,
washed with PBS, and blocked with 5% BSA in PBS/ 0.1% Tween 20 for 1 h. DNA
immunostaining was performed with rat anti-BrdU antibody (1:50; AbCys SA,
ABC117 7513) for CldU and mouse anti-BrdU antibody (1:50; Becton Dickson,
347580) for IdU in a humid chamber at 37 °C for 1 h. The following secondary
antibodies were used: anti-rat Alexa 488 (1:100; Molecular Probes, A21470) and
anti-mouse Alexa 546 (1:100; Molecular Probes, A21123) at 37 °C for 45 min. The
slides were air dried and mounted with Prolong Gold Antifade reagent (Invitro-
gen). Images were sequentially acquired (for double-label) with LAS AF software
using TCS SP5 confocal microscope (Leica). A 63×/1.4 oil immersion objective was
used. Images were captured at room temperature. The DNA tract lengths were
measured using ImageJ and the pixel length values were converted into micro-
meters using the scale bars created by the microscope. n≥ 150 ﬁber tracts scored
for each data set. The statistics for all these experiments measuring changes in the
size of the IdU or CldU tracts were calculated on the total number of DNA tracts
measured in each given sample (usually n≥ 250). For the fork restart experiments,
the percentage of stalled forks was calculated on the basis of at least 250 tracts
counted in each independent experiment. All DNA ﬁber experiments were per-
formed in duplicate or triplicate, as indicated in the ﬁgure legends. Additional
information on the minimal number of tracts that should be measured for a reliable
estimation of changes in fork speed within a given sample can be found in refs.
26, 52.
Electron microscopy. For the EM analysis of replication intermediates, 5–10 × 106
U2OS or PEO1/4 cells were collected and genomic DNA was cross-linked by two
rounds of incubation in 10 μg ml−1 4,5′,8-trimethylpsoralen (Sigma-Aldrich) and
3 min of irradiation with 366 nm UV light on a precooled metal block10, 26. Cells
were lysed and genomic DNA was isolated from the nuclei by proteinase K (Roche)
digestion and phenol-chloroform extraction. DNA was puriﬁed by isopropanol
precipitation, digested with PvuII HF in the proper buffer for 3–5 h at 37 °C and
replication intermediates were enriched on a benzoylated naphthoylated
DEAE–cellulose (Sigma-Aldrich) column. EM samples were prepared by spreading
the DNA on carbon-coated grids in the presence of benzyl-dimethyl-
alkylammonium chloride and visualized by platinum rotary shadowing. Images
were acquired on a transmission electron microscope (JEOL 1200 EX) with side-
mounted camera (AMTXR41 supported by AMT software v601) and analyzed with
ImageJ (National Institutes of Health). EM analysis allows distinguishing duplex
DNA—which is expected to appear as a 10 nm thick ﬁber, after the platimun/
carbon coating step necessary for EM visualization—from ssDNA, which has a
reduced thickness of 5–7 nm. The criteria used for the unequivocal assignment of
reversed forks include the presence of a rhomboid structure at the junction itself in
order to provide a clear indication that the junction is opened up and that the four-
way junction structure is not simply the result of the occasional crossing of two
DNA molecules25. In addition, the length of the two arms corresponding to the
newly replicated duplex should be equal (b= c), whereas the length of the parental
arm and the regressed arm can vary (a ≠ b= c≠ d). Conversely, canonical Holliday
junction structures will be characterized by arms of equal length two by two (a= b,
c= d).
Metaphase spreads. Cells were treated with 4 mM HU for 6 h, washed twice with
PBS, and released for 24 h in fresh medium. During the last 4 h, 10 μM nocodazole
was added to the medium. Cells were collected, washed and resuspended in 10 ml
of warmed hypotonic solution (10 mM KCl, 10% FBS) for 10 min at 37 °C. Cells
were ﬁxed by adding 500 μl of cold ﬁxation buffer (acetic acid 1: 3 ethanol). Cell
pellets were washed four times with the cold ﬁxation buffer and stored in this
buffer at 4 °C overnight. The nuclei were spread on cold slides. The slides were air
dried overnight and mounted with Prolong Gold Antifade (Invitrogen) with DAPI.
Images were acquired with a ﬂuorescence microscope (LEICA DMU 4000B; 63×/
1.40-0.60 NA oil) coupled to the LEICA DFC345FX camera. The images were
analyzed with ImageJ. At least 50 metaphases per sample were scored in each
experiment.
Neutral comet assay for DSB detection. A total of 700 cells were resuspended in
70 μl 0.5% low melting point agarose (Trevigen, 4250-050-02) and spread on a
comet slide (Trevigen, 4250-200-03). Cells were lysed in a cold lysis solution
(Trevigen, 4250-050-01) at 4 °C for 30 min. DNA migration was performed in TBE
buffer at 1 V cm−1 for 30 min. Slides were washed in milliQ water, ﬁxed with
ethanol 70% for 30 min and dried at room temperature. Comets were labeled with
SYBR® Gold Nucleic Acid Gel Stain (ThermoFisher) for 30 min. Images were
acquired with a ﬂuorescence microscope (LEICA DMU 4000B; 20×/0.4 CORR)
coupled to the LEICA DFC345FX camera. The images were analyzed using ImageJ.
At least 150 comets were scored per sample in each experiment.
Cell viability. Cell viability was determined using the Cell Proliferation Kit II
(XTT, Roche)53. Brieﬂy, cells were seeded at 13,000 cells per well in a 24-well plate
the day prior to treatment. Cells were treated chronically with the indicated doses
of HU and cell viability was assessed 3 days after. The absorbance was measured at
450 nm with a reference wavelength at 650 nm. Results were expressed as per-
centage of the untreated control.
Immunoﬂuorescence microscopy. After treatment with 4 mM HU, U2OS cells
were extracted with 1× PBS containing 0.2% Triton X-100 and protease inhibitors
(Pierce) for 5 min on ice prior to ﬁxation with 3.2% paraformaldehyde. The cells
were then washed extensively with IF wash buffer (1× PBS, 0.5% NP-40, and 0.02%
NaN3), then blocked with IF Blocking Buffer (IF wash buffer plus 10% FBS) for at
least 30 min. Anti-MUS81 mouse monoclonal (1:200; ab14387 Abcam) or anti-
POLD3 mouse monoclonal (1:350; H00010714-M01 Abnova) antibodies were
diluted in IF Blocking Buffer overnight at 4 °C. After staining with secondary
antibodies (1:1000, conjugated with Alexa Fluor 594; A11032 Life Technologies)
and Hoechst 33342 (1:1000, Sigma-Aldrich), samples were mounted using Prolong
Gold mounting medium (Invitrogen). Epiﬂuorescent microscopy was performed
on an Olympus ﬂuorescent microscope (BX-53) using a UPlanS-Apo 100×/1.4 oil
immersion lens, Hamamatsu ORCA-Flash 4.0LT digital camera, and cell-Sens
Dimension software. The raw images were exported into Adobe Photoshop, and for
any adjustments in image contrast or brightness, the levels function was applied as
previously described54. For foci quantitation, at least 150 cells were analyzed in
triplicate.
Statistical analysis. Statistical analysis was performed using Prism (GraphPad
Software). The statistical signiﬁcance in each case was calculated as indicated in
each ﬁgure legend.
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Data availability. The authors declare that all relevant data supporting the ﬁndings
of this study are available with the article and its Supplementary Information ﬁles,
or from the corresponding author upon request.
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